Home・Lista de Ações・BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc

Fechado

SetorSaúde

9.66 -3.98

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

9.59

Máximo

10.06

Indicadores-chave
By Trading Economics
Rendimento	800M 78M
Vendas	62M 218M
P/E Médio do Setor	7.603 57.371
EPS	0.3
Margem de lucro	35.92
Funcionários	435
EBITDA	799M 99M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+102.98% upside

Dividendos
By Acuity
Próximos Ganhos	2 de nov. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	301M 2.5B
Abertura anterior	13.64
Fecho anterior	9.66

Sentimento de Notícias

By Acuity

55%

45%

284 / 340 Ranking em Healthcare

BioCryst Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

19 de ago. de 2026, 23:01 UTC

BioCryst Pharmaceuticals Inc shares are lower in after-market trading, retracing from an earlier uptick with no specific news identified to explain the decline.

18 de ago. de 2026, 20:06 UTC

BioCryst Pharmaceuticals Inc shares are declining amid broader market weakness, with no specific news identified to explain today's price movement.

14 de ago. de 2026, 19:06 UTC

BioCryst Pharmaceuticals is lower today, following broader market concerns over an unexpected drop in U.S. retail sales impacting Federal Reserve interest rate policy.

13 de ago. de 2026, 21:31 UTC

BioCryst Pharmaceuticals shares traded roughly flat in after-market hours, remaining within their one-month range and above the 20-day moving average.

12 de ago. de 2026, 19:41 UTC

BioCryst Pharmaceuticals shares are higher today, rebounding from an earlier dip and reflecting notable volatility during the session. The stock remains above its 20-day moving average.

11 de ago. de 2026, 23:26 UTC

BioCryst Pharmaceuticals Inc shares are lower in after-market hours, reflecting a decline since Tuesday's close amid broader market weakness and cautious sentiment.

10 de ago. de 2026, 19:51 UTC

News

BioCryst Pharmaceuticals Inc. shares are higher after Wall Street Zen upgraded its rating to "strong-buy." Other firms also adjusted price targets amid market uncertainty.

7 de ago. de 2026, 19:56 UTC

BioCryst Pharmaceuticals is trading higher, continuing a positive trend amid easing concerns over interest rate hikes following a disappointing jobs report.

6 de ago. de 2026, 22:36 UTC

BioCryst Pharmaceuticals shares are lower in after-market trading, continuing a decline since Thursday's close and positioned below the 20-day moving average.

5 de ago. de 2026, 22:36 UTC

BioCryst Pharmaceuticals Inc shares are higher in after-market trading, despite no specific news identified to explain the movement. They remain below their 20-day moving average.

4 de ago. de 2026, 19:36 UTC

Correlated Moves

BioCryst Pharmaceuticals Inc shares are higher today, supported by gains in the biotechnology sector. The stock remains above its earlier low despite recent trends.

3 de ago. de 2026, 19:56 UTC

BioCryst Pharmaceuticals Inc shares are lower today, continuing a downward trend since Friday. The broader market is seeing gains, contrasting with BioCryst's performance.

31 de jul. de 2026, 22:36 UTC

BioCryst Pharmaceuticals Inc shares are higher in after-market trading. No specific news was identified to explain this movement, reflecting routine performance since Friday's close.

30 de jul. de 2026, 20:09 UTC

BioCryst Pharmaceuticals shares are lower amid broader market volatility following mixed economic signals, including rising jobless claims and disappointing GDP growth.

29 de jul. de 2026, 19:35 UTC

BioCryst Pharmaceuticals Inc shares are lower amid a declining market, with no specific company news identified to explain the movement during today's session.

28 de jul. de 2026, 23:06 UTC

BioCryst Pharmaceuticals Inc shares are higher in after-market trading, continuing an upward trend from Tuesday's close, despite an earlier session pullback.

27 de jul. de 2026, 20:01 UTC

BioCryst Pharmaceuticals Inc shares are trading higher in Monday's session, reflecting notable strength despite remaining near the lower end of their one-month trading range.

24 de jul. de 2026, 21:01 UTC

BioCryst Pharmaceuticals Inc. shares are lower in after-market hours, reflecting broader market trends following a decline in the Nasdaq influenced by negative earnings reports.

22 de jul. de 2026, 21:51 UTC

BioCryst Pharmaceuticals Inc shares are lower in after-market trading, continuing a decline amid significant volatility in U.S. markets and lack of specific news.

21 de jul. de 2026, 17:46 UTC

BioCryst Pharmaceuticals Inc shares are higher today, continuing an upward trend since Monday. The stock remains below its 20-day moving average.

20 de jul. de 2026, 19:16 UTC

Correlated Moves

Shares lower amid decline in Biotechnology sub-sector and SPDR ETF.

Comparação entre Pares

Variação de preço

BioCryst Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

102.98% parte superior

Previsão para 12 meses

Média 20.44 USD 102.98%

Máximo 32 USD

Mínimo 12 USD

Com base em 9 analistas de Wall Street que oferecem metas de preço de 12 meses para BioCryst Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

9 ratings

Comprar

Manter

Vender

Com base em 9 analistas que deram avaliações de ações para BioCryst Pharmaceuticals Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

284 / 340 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.